Daewoong Pharmaceutical Launches Combination Dyslipidemia Drug 'BaroEzet Tab'
Daewoong Pharmaceutical has strengthened its dyslipidemia treatment portfolio by launching 'BaroEzet Tab,' expanding its product lineup to include low-dose pitavastatin-based combination drugs.
Daewoong Pharmaceutical announced on April 1, 2026, the launch of 'BaroEzet Tab (pitavastatin 1mg · ezetimibe 10mg),' a treatment for dyslipidemia. BaroEzet Tab is a new low-dose combination drug containing pitavastatin 1mg and ezetimibe 10mg, indicated for the treatment of primary hypercholesterolemia.
Recently, the treatment paradigm for dyslipidemia has shifted from a stepwise increase in the dosage of statin monotherapy to an initial combination therapy using low-dose statin and ezetimibe. It is known that as the dosage of statins increases, the incremental efficacy diminishes, while the risk of side effects such as myalgia increases.
In fact, doubling the statin dose achieves only an additional 6% reduction in LDL cholesterol, whereas combining it with ezetimibe can provide an additional reduction of over 18%.
With this change in treatment strategy, demand for low-dose statin combination therapies is also increasing. Last year, domestic prescriptions for low-dose rosuvastatin-based combination drugs and atorvastatin-based combination drugs grew by 73% and 39%, respectively. However, in the pitavastatin-ezetimibe combination drug market, only 2/10mg and 4/10mg dosages were available, leaving a gap for lower-dose options.
BaroEzet Tab was developed to address this unmet need, offering a new 1/10mg low-dose option among pitavastatin-based combination drugs and expanding treatment choices.
BaroEzet Tab demonstrated clinical efficacy in a Phase 3 study involving 129 domestic patients with primary hypercholesterolemia. After 8 weeks, the LDL cholesterol (LDL-C) reduction rate for BaroEzet Tab was 43.9%, greater than that of pitavastatin 1mg monotherapy (29.1%). This effect is similar to that of pitavastatin 4mg[1], making it an optimal alternative for patients currently taking pitavastatin 2mg or 4mg who wish to maintain LDL-C lowering efficacy while reducing concerns about side effects.
Additionally, in the BaroEzet Tab group, non-HDL cholesterol—an increasingly important cardiovascular risk factor—decreased by 40.6%, and apolipoprotein B (ApoB) decreased by 34.2%, confirming overall lipid profile improvement compared to monotherapy.
The drug is also expected to be versatile for different patient characteristics. Due to pitavastatin's low reliance on CYP enzymes for metabolism, BaroEzet Tab may reduce the risk of drug-drug interactions in patients taking multiple medications. It may also be considered as a treatment option for elderly patients or thin female patients, in whom statin-associated muscle symptoms (SAMS) are more common.
With the launch of BaroEzet Tab, Daewoong Pharmaceutical has further strengthened its dyslipidemia treatment portfolio by adding a low-dose pitavastatin-based combination drug, in addition to its existing rosuvastatin-ezetimibe combination 'Crezet' and atorvastatin-ezetimibe combination 'Litobazet.'
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Hyungchul Park, Head of ETC Marketing at Daewoong Pharmaceutical, stated, "BaroEzet Tab is significant as a low-dose pitavastatin-based combination drug that considers both efficacy and the risk of side effects. We expect it to contribute to more sophisticated dyslipidemia treatment strategies that reflect patient characteristics and metabolic risk factors in the future."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.